Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta‐analysis of 35 randomized controlled trials
Background We sought to examine the efficacy and safety of 2 PCSK9 (proprotein
convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and …
convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and …
[HTML][HTML] Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro-and macrovascular complications
G Bardini, CM Rotella, S Giannini - The review of diabetic studies …, 2012 - ncbi.nlm.nih.gov
Patients with diabetes frequently exhibit the combined occurrence of hyperglycemia and
dyslipidemia. Published data on their coexistence are often controversial. Some studies …
dyslipidemia. Published data on their coexistence are often controversial. Some studies …
[HTML][HTML] Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017 …
SL James, D Abate, KH Abate, SM Abay, C Abbafati… - The Lancet, 2018 - thelancet.com
Summary Background The Global Burden of Diseases, Injuries, and Risk Factors Study
2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and …
2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and …
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a …
GBD Collaborators - 2018 - figshare.le.ac.uk
BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017
(GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years …
(GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years …
[HTML][HTML] Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic …
T Vos, AA Abajobir, KH Abate, C Abbafati, KM Abbas… - The Lancet, 2017 - thelancet.com
Background As mortality rates decline, life expectancy increases, and populations age, non-
fatal outcomes of diseases and injuries are becoming a larger component of the global …
fatal outcomes of diseases and injuries are becoming a larger component of the global …
2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American …
EA Amsterdam, NK Wenger, RG Brindis… - Journal of the American …, 2014 - jacc.org
The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …
extensive evidence review was conducted through October 2012, and other selected …
Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population
L Kaasenbrood, SM Boekholdt, Y Van Der Graaf… - Circulation, 2016 - Am Heart Assoc
Background: Among patients with clinically manifest vascular disease, the risk of recurrent
vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of …
vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of …
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
X Wang, D Wen, Y Chen, L Ma, C You - Cardiovascular diabetology, 2022 - Springer
Abstract Background The Food and Drug Administration has approved Proprotein
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …
Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
Aims A high visit-to-visit variability in cholesterol levels has been suggested to be an
independent predictor of major adverse cardiovascular events in patients with coronary …
independent predictor of major adverse cardiovascular events in patients with coronary …
Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease
AMK Jepsen, A Langsted, A Varbo, LE Bang… - Clinical …, 2016 - academic.oup.com
BACKGROUND Increased concentrations of remnant cholesterol are causally associated
with increased risk of ischemic heart disease. We tested the hypothesis that increased …
with increased risk of ischemic heart disease. We tested the hypothesis that increased …